Articles published by PepGen Inc.
![](https://mms.businesswire.com/media/20240820703812/en/2155755/22/PepGen_Logo_CMYK_FullColor.jpg)
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
Today 8:00 EDT
From PepGen Inc.
Via Business Wire
Tickers
PEPG
![](https://mms.businesswire.com/media/20240808826731/en/2155755/22/PepGen_Logo_CMYK_FullColor.jpg)
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024
From PepGen Inc.
Via Business Wire
Tickers
PEPG
![](https://mms.businesswire.com/media/20240730713512/en/2155755/22/PepGen_Logo_CMYK_FullColor.jpg)
![](https://mms.businesswire.com/media/20240702582877/en/2155755/22/PepGen_Logo_CMYK_FullColor.jpg)
![](https://mms.businesswire.com/media/20240611396164/en/2155755/22/PepGen_Logo_CMYK_FullColor.jpg)
PepGen Announces Executive Team Promotions
June 11, 2024
From PepGen Inc.
Via Business Wire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 20, 2024
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
January 17, 2024
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
December 18, 2023
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
November 15, 2023
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 08, 2023
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 08, 2023
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
![](https://ml.globenewswire.com/media/58739ec4-55ff-4340-bf87-4c5ede0e9df4/small/pegn-jpg.jpg)
PepGen to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023
From PepGen Inc.
Via GlobeNewswire
Tickers
PEPG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.